Nexalin Technology Inc. is a pioneering medical technology firm dedicated to transforming the treatment of neurological and psychiatric disorders through its proprietary transcranial electrical stimulation devices. By offering non-invasive solutions for prevalent mental health issues such as anxiety, depression, and substance addiction, the company underscores its commitment to improving patient outcomes and advancing accessible mental health care. With a robust research background and a strategic focus on tapping into the rising demand for innovative healthcare solutions, Nexalin is well-positioned for growth in the rapidly expanding digital health sector, presenting a compelling investment opportunity for institutional investors.
| Revenue (TTM) | 217,160 |
| Gross Profit (TTM) | 187,100 |
| EBITDA | $-9.08M |
| Operating Margin | -18480.00% |
| Return on Equity | -240.20% |
| Return on Assets | -119.20% |
| Revenue/Share (TTM) | $0.34 |
| Book Value | $2.07 |
| Price-to-Book | 2.63 |
| Price-to-Sales (TTM) | 11.35 |
| EV/Revenue | 13.75 |
| EV/EBITDA | 0.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -82.80% |
| Shares Outstanding | $1.05M |
| Float | 554,000 |
| % Insiders | 24.58% |
| % Institutions | 3.45% |
Volatility is currently expanding
Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs
Agreement establishes an initial 100-device commercialization program for the ANVISA-approved Nexalin Sync™ across seven countries and more than 300 million people, with a structured pricing framework and a mechanism for larger strategic transactions with government and private-sector customers
Further analysis of ADAS-Cog data from the Company's randomized, sham-controlled clinical trial — previously published in the Journal of Alzheimer's Disease and in Radiology — identifies specific improvements in cognitive domains associated with memory in Alzheimer's patients
HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company's common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.
Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin's recently completed Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 – Congress on Brain, Behavior and Emotions, held in Porto Alegre, Brazil
Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and quality of life
Study using Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up
Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin's proprietary position in non-invasive frequency-based deep-brain neurostimulation
U.S. House Appropriations Committee report language directs VA to support additional research evaluating non-invasive deep brain neurostimulation technologies for veterans with treatment-resistant traumatic brain injury
Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSD Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSD
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NXL and any ticker you trade — then tracks every position and per-strategy win rate.
